Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
Gregory W. Mattingly(Washington University in St. Louis), D. Wayne Goodman(Johns Hopkins University), Richard H. Weisler, Brian Scheckner(Takeda (United States)), Ben Adeyi(Takeda (United States)), Joel Young(Dalhousie University), Robert Lasser(Takeda (United States)), Bryan Dirks(Takeda (United States)), T. Babcock(Takeda (United States))
Cited by 31
Related Papers
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease
|American Journal of Psychiatry|2003|288
Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
|CNS Spectrums|2009|93
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder
|Journal of the American Academy of Child & Adolescent Psychiatry|2015|63
Once-Daily Treatment With Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder
|Clinical Neuropharmacology|2011|61